Medical News

RSS

BioSpace, Delaware BioScience partner to launch online career center for life science markets

BioSpace has partnered with the Delaware BioScience Association to launch an online career center specifically for life science markets.

8 Sep 2010

NEXUS Biosystems acquires REMP from Tecan Group

NEXUS Biosystems, Inc., a leading innovator and worldwide provider of automated sample management systems, today announced the completion of the acquisition of REMP AG of Switzerland, a wholly-owned subsidiary of the Tecan Group.

From Tecan 8 Sep 2010

Zyngenia completes $15M Series A financing extension from NEA

Zyngenia, Inc., a privately held biotherapeutics company focused on next-generation antibody drug development, announced today the completion of a $15 million Series A financing extension from New Enterprise Associates (NEA), one of the world's leading venture capital firms. The capital will be used to continue to rapidly progress Zyngenia's pipeline of Zybodies™, which are novel, multi-specific, antibody-based molecules that address two or more biological targets with a single protein drug.

8 Sep 2010

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

Progenics Pharmaceuticals, Inc. today announced the initiation of an international 700-patient, phase 3 trial of oral methylnaltrexone in patients with chronic, non-cancer pain who are experiencing constipation as a result of their opioid-pain management regimens. The goal of the study is to evaluate the safety and efficacy of oral methylnaltrexone to treat opioid-induced constipation (OIC) in this patient setting.

8 Sep 2010

BioMed Realty Trust expands San Diego property portfolio to 1.8M rentable square feet

BioMed Realty Trust, Inc. today announced that it has entered into definitive agreements to acquire five properties, comprised of 14 life science buildings with approximately 405,000 square feet of laboratory and office space, in San Diego's primary life science submarkets of University Towne Centre, Torrey Pines and Sorrento Valley.

8 Sep 2010

AHF praises US government's increase in PEPFAR funding commitment for Uganda

AIDS Healthcare Foundation (AHF), the largest global AIDS organization, which currently cares for over 49,000 AIDS patients in Uganda through its Uganda CARES network of eleven treatment clinics throughout the country, today lauded the United States government for increasing its funding commitment in Uganda for the President's Emergency Plan for AIDS Relief (PEPFAR), the United States' respected global AIDS program.

8 Sep 2010

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

MAP Pharmaceuticals, Inc. today announced that all non-asthmatic patients and a subset of asthmatic patients have completed 12 months of treatment in the open-label safety trial of LEVADEX™. In addition, the Company has completed patient treatment in a thorough QT trial, the last trial necessary to support a New Drug Application (NDA) for LEVADEX.

8 Sep 2010

Quick-Med expands and strengthens NIMBUS technology intellectual property

Quick-Med Technologies, Inc., a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent 7,790,217 entitled "Method of Attaching an Antimicrobial Cationic Polyelectrolyte to the Surface of a Substrate."

8 Sep 2010

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

MAP Pharmaceuticals, Inc. today reported results from a pharmacodynamics trial comparing the acute effects on pulmonary artery pressure of LEVADEX, dihydroergotamine mesylate administered intravenously and placebo. In the trial, there was no statistically significant difference between the LEVADEX and placebo groups in the primary endpoint of pulmonary artery pressure over two hours after administration.

8 Sep 2010

USPTO awards Medicis new patent for SOLODYN Extended Release Tablets

Medicis today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 7,790,705 related to the use of SOLODYN® (minocycline HCI, USP) Extended Release Tablets. The new patent, entitled "Minocycline Oral Dosage Forms for the Treatment of Acne," relates to the use of dosage forms of SOLODYN which provide approximately 1 mg/kg dosing based on the body weight of the person, and expires in 2027.

8 Sep 2010

Columbus Regional Hospital joins Indiana Network for Patient Care

Columbus Regional Hospital is bringing the nation's largest health information exchange to the Columbus, Ind. area to better serve patients. Joining over 65 hospitals, long term care facilities and other healthcare providers, Columbus Regional Hospital is now part of a statewide network that allows physicians to securely access necessary information to make decisions critical to patient care.

8 Sep 2010

McLeod Health implements Merge Healthcare's radiology, cardiology workflow solutions

Merge Healthcare, a leading health IT solutions provider, today announced a new contract with McLeod Health (Florence, SC). This agreement integrates the Merge cardiology workflow solutions with McLeod's existing Merge radiology solution, allowing McLeod to streamline workflow and improve quality data across their entire cardiovascular service line, while also providing a unified image management platform.

8 Sep 2010

Vela Laboratories renews GMP certificate for analytical and Quality Control laboratories

Vela Laboratories, a provider of analytical services to the global biopharmaceutical industry, today announced the renewal of the GMP certificate for its analytical and Quality Control laboratories until 2013.

8 Sep 2010

Liberator Medical Holdings' subsidiary receives 2010 Governor's Business Diversification Award

Liberator Medical Holdings, Inc. today announced its wholly owned subsidiary, Liberator Medical Supply, has received the 2010 Governor's Business Diversification Award in the Business Expansion category.

8 Sep 2010

Tampa, Florida-based medical institution purchases Streamline Health's document workflow solutions

Streamline Health Solutions, Inc. a leading provider of document workflow solutions for hospitals, today announced that a leading Tampa, Florida-based medical institution has purchased three additional workflow licenses to expand the use of Streamline Health's document workflow solutions to help optimize business processes across the enterprise and improve operational efficiencies. Streamline Health expects at least two of the workflow solutions to be fully implemented and operational prior to the conclusion of the current fiscal year.

8 Sep 2010

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Enobia Pharma today provided an update on key developments in its comprehensive effort to develop ENB-0040 (asfotase alfa), an experimental bone-targeted enzyme replacement therapy, for the treatment of hypophosphatasia. Hypophosphatasia is a rare, inherited, and sometimes fatal metabolic bone disease that affects individuals of all ages.

8 Sep 2010

Positive results from YM BioSciences' CYT997 Phase I study for vascular disruption in tumors

YM BioSciences Inc., today announced the publication of Phase I results demonstrating that CYT997, a novel vascular disrupting agent (VDA), was well tolerated at doses that were associated with pharmacodynamic evidence of vascular disruption in tumors. The article entitled "Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent," was published in the premier cancer journal, the British Journal of Cancer.

8 Sep 2010

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

Champions Biotechnology, Inc., an oncology drug development company with a predictive preclinical platform aimed at accelerating the development and enhancing the value of oncology drugs, announced the establishment of an agreement with Cephalon, Inc., a global biopharmaceutical company, for the testing of the Cephalon novel B-Raf inhibitor CEP-32496 in Champions' Biomerk Tumorgraft™ platform.

8 Sep 2010

Emergent BioSolutions initiates Phase I clinical trial for anthrax monoclonal antibody therapeutic

Emergent BioSolutions Inc. announced today that the Phase I clinical trial for its anthrax monoclonal antibody therapeutic has commenced with the dosing of the first subject. Emergent's fully human monoclonal antibody product candidate is being developed as a parenteral post-exposure therapeutic to treat symptoms of inhalational anthrax disease.

8 Sep 2010

Perrigo receives FDA approval to manufacture, market Imiquimod Cream, 5%

Perrigo Company announced it received FDA approval from the U.S. Food and Drug Administration to manufacture and market Imiquimod Cream, 5%. Perrigo will vertically integrate this product with their own API.

8 Sep 2010

Medical News

BioSpace, Delaware BioScience partner to launch online career center for life science markets

NEXUS Biosystems acquires REMP from Tecan Group

Zyngenia completes $15M Series A financing extension from NEA

Progenics commences Phase 3 trial of oral methylnaltrexone for opioid-induced constipation

BioMed Realty Trust expands San Diego property portfolio to 1.8M rentable square feet

AHF praises US government's increase in PEPFAR funding commitment for Uganda

MAP Pharmaceuticals completes 12 months of treatment in LEVADEX open-label safety trial

Quick-Med expands and strengthens NIMBUS technology intellectual property

MAP Pharmaceuticals reports results from PD trial that compares effects of LEVADEX, IV DHE

USPTO awards Medicis new patent for SOLODYN Extended Release Tablets

Columbus Regional Hospital joins Indiana Network for Patient Care

McLeod Health implements Merge Healthcare's radiology, cardiology workflow solutions

Vela Laboratories renews GMP certificate for analytical and Quality Control laboratories

Liberator Medical Holdings' subsidiary receives 2010 Governor's Business Diversification Award

Tampa, Florida-based medical institution purchases Streamline Health's document workflow solutions

Update on Enobia Pharma's effort to develop ENB-0040 for treating HPP patients

Positive results from YM BioSciences' CYT997 Phase I study for vascular disruption in tumors

Champions Biotechnology signs agreement to test Cephalon's CEP-32496 in Biomerk Tumorgraft platform

Emergent BioSolutions initiates Phase I clinical trial for anthrax monoclonal antibody therapeutic

Perrigo receives FDA approval to manufacture, market Imiquimod Cream, 5%

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News